(Report報告)The 124th IROAST Seminar was held 第124回IROASTセミナーが開催されました

Jul 08, 2024

2024年7月8日、新留 琢郎教授(大学院先端科学研究部)、及びRuda Lee准教授(産業ナノマテリアル研究所)が世話人となり、韓国科学技術研究院 (KIST)所属、Ick Chan Kwon IROAST客員教授による第124回IROASTセミナーが、熊本大学内の大江キャンパスにて開催されました。

Ick Chan KWON博士は、医薬品送達システム(DDS)の有名な研究者であり、特に東京大学に強いネットワークをもっています。本日は、大腸がん治療に有望なEGFプローブとCetuxプローブに関する興味深い講演を行いました。

The 124th IROAST Seminars, coordinated by Prof. Takuro NIIDOME (FAST, Kumamoto University) and Associate Prof. Ruda LEE (Institute of Industrial Nanomaterials (IINa)/IROAST International Joint Research Faculty Member), was held on July 8, 2024, in Oe campus of Kumamoto University, welcoming IROAST Visiting Professor Ick Chan KWON from Korea Institute of Science and Technology (KIST) in Korea.

Dr. Ick Chan Kwon, who is a distinguished researcher in Drug Delivery Systems (DDS), particularly known for having his strong network at the University of Tokyo. Today he delivered an insightful lecture about promising EGF probes and Cetux probes for colorectal cancer treatment.


新留 琢郎 教授 (熊本大学先端科学研究部)
 Prof. Takuro NIIDOME (FAST, Kumamoto University)

Ruda LEE准教授(熊本大学産業ナノマテリアル研究所)
Assoc. Prof. Ruda LEE (IINa/IROAST)


イクチャン クォン教授 韓国科学技術研究院(KIST)  (韓国)
Dr. Ick Chan KWON (Korea Institute of Science and Technology (KIST), Korea) 

会場の様子| At Venue

■集合写真|Group Photo

The124th IROAST Seminar

Jun 24, 2024

 国際先端科学技術研究機構(IROAST)は、Korea Institute of Science & Technology(KIST)所属、Ick Chan KWON IROAST客員教授による、第124回 IROASTセミナーを下記のとおり開催いたします。

1.   日 時:令和6年 7月 8日(月) 13:30~14:30

2.会 場:熊本大学大江キャンパスE4 17番 (産業イノベーションラボラトリー) 1Fセミナー室

3.講演者・演題(Speaker &Title):
    Dr. Ick Chan KWON, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Korea                
      “Visualization of EGFR Internalization as a Theranostic Approach”


       Targeting the epidermal growth factor receptor (EGFR) is a promising approach for colorectal cancer treatment, yet individual responses to EGFR-targeted therapies vary widely. Current diagnostic methods fall short in predicting therapeutic efficacy.

To address this, we developed two innovative probes: an EGF-conjugated fluorescence-activatable probe (EGF-probe) and a fluorogenic cetuximab-conjugated probe (Cetux-probe). The EGF-probe, paired with an EGF-conjugated doxorubicin prodrug (EGF-prodrug), uses lysosomal enzyme activity to activate fluorescence and cytotoxicity upon EGFR-mediated endocytosis. Similarly, the Cetux-probe evaluates EGFR internalization and degradation, predicting the response to cetuximab therapy.

Both probes demonstrated strong correlations between fluorescence activation and therapeutic efficacy in colorectal cancer cells, dependent on lysosomal activity rather than EGFR expression. These tools offer a significant advancement in personalized cancer therapy by enhancing the ability to predict and monitor treatment responses, paving the way for more effective and tailored patient care.

  1. Y. Sung, et al, Biomaterials, 303, 122382 (2023)
  2. H.Y. Kim, et al, J. Controlled Release, 328, 222-236 (2020)


5.  世話人: 新留 琢郎 教授 (大学院先端科学研究部)

【IROASTセミナーに関するお問合せ】 平川

 IROAST will have the 124th IROAST Seminars by IROAST Visiting Professor Ick Chan KWON, Korea Institute of Science and Technology (KIST), Korea as follows. Anyone interested in this seminar is more than welcome. Registration is not required.
We hope to see you at the seminar.

  1. Date and time: Monday, July 8, 2024 13:30 – 14:30
  2. Venue: Industrial Innovation Laboratory 1F, Oe Campus<E4>
  3. Speaker, Title & Abstract: Referred to above
  4. Organizer: Prof. Takuro NIIDOME (FAST, Kumamoto University)
  5. Remarks: This seminar will be held in English.

IROAST Seminar inquiries
Hirakawa (Ms.)

Page top